The Magazine for Sleep Professionals
Saturday, October 24, 2026
Alkermes plc today announced positive topline results from the randomized double-blind treatment period of the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1). Alixorexton, formerly referred to as ALKS 2680, is the company’s novel, investigational, oral orexin 2 receptor (OX2R) agonist in phase 2 development as […]
The Sleep To Live Well Foundation issues an urgent warning in its groundbreaking 2025 State of Sleep Wellness Report, titled “THE SILENT EPIDEMIC: How Lack of Sleep Endangers Over Half of All Americans and Threatens Everyone.” The report unveils the Foundation’s initiatives to address this insufficient sleep crisis with Sleep Wellness—a holistic approach to […]
A new study to be presented at the SLEEP 2025 annual meeting found that excessive daytime sleepiness is associated with higher odds of all-cause mortality in middle-aged women but not in younger or older women. Results show that the adjusted odds of all-cause mortality were 16% higher in women between […]
A new study to be presented at the SLEEP 2025 annual meeting found that strong family relationships and high parental engagement are among the aspects of social connectedness that are associated with sufficient sleep duration in pre-teen children. Results show that eating dinner with family and participating in neighborhood activities […]
Neuroscientists have found the average person processes roughly 74 gigabytes of information every day.1 That is the equivalent of watching 16 movies, reading more than 200,000 words, or scrolling on TikTok for approximately 200 hours. In other words, we are inundated with information from every angle — social media, websites, […]
Recent research has elevated the management of obesity in patients with sleep disorders to a prominent position in clinical practice. Obesity has been capturing attention across social media, mainstream news, and even in cultural references such as South Park specials and Jimmy Kimmel’s 2023 Oscars commentary. This heightened focus underscores […]
Apnimed, Inc., a pharmaceutical company building the industry-leading portfolio of first-in-class oral drug candidates that address the root causes of obstructive sleep apnea (OSA) and other sleep-related breathing diseases, today announced positive topline results from its pivotal Phase 3 SynAIRgy clinical trial evaluating the efficacy and safety of Apnimed’s lead […]
Panthera Dental is proud to announce that their abstracts were accepted for poster presentation at the AADSM and for poster and oral presentation at the SLEEP Annual Meetings. The oral presentation is part of a session entitled “Contemporary Management of Sleep Apnea” (O-13). Information regarding the 2025 IIR Grant will […]
Nightmares are not just a fleeting inconvenience—they can have profound implications on mental health and overall well-being. Recent studies have suggested that nightmares are underdiagnosed and undertreated, even in sleep centers.1,2 Because it is unlikely that patients will report nightmares without provocation, it is important for providers to inquire about […]
Apnimed, Inc. announced the results of its Sleep Health Inquiries on Needs and Emotions (SHINE) survey of 1,500 people living with obstructive sleep apnea (OSA). The survey results revealed the significant and often devastating impact that people living with OSA experience daily. Many respondents reported feeling worn out or exhausted […]
